4
Changes in Ownership
Protalix BioTherapeutics, Inc. Filed Acc 0001104659-20-070906
Options or other derivatives
- SVP, Chief Development Officer acquired 196,995 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Derivatives | |||||||
| Almon Einat Brill SVP, Chief Development Officer | 2020-06-07 | Grant or award · Stock Options (Right to Buy) | +196,995 | 196,995 | D | ||
Loading xslF345X03/tm2022027d1_4.xml…